Volume 17, Number 2—February 2011
Novel HIV-1 Recombinant Forms in Antenatal Cohort, Montreal, Quebec, Canada
Highlight and copy the desired format.
|EID||Quesnel-Vallières M, Kouzayha I, Tran E, Barry I, Lasgi C, Merindol N, et al. Novel HIV-1 Recombinant Forms in Antenatal Cohort, Montreal, Quebec, Canada. Emerg Infect Dis. 2011;17(2):271-274. https://dx.doi.org/10.3201/eid1702.100629|
|AMA||Quesnel-Vallières M, Kouzayha I, Tran E, et al. Novel HIV-1 Recombinant Forms in Antenatal Cohort, Montreal, Quebec, Canada. Emerging Infectious Diseases. 2011;17(2):271-274. doi:10.3201/eid1702.100629.|
|APA||Quesnel-Vallières, M., Kouzayha, I., Tran, E., Barry, I., Lasgi, C., Merindol, N....Soudeyns, H. (2011). Novel HIV-1 Recombinant Forms in Antenatal Cohort, Montreal, Quebec, Canada. Emerging Infectious Diseases, 17(2), 271-274. https://dx.doi.org/10.3201/eid1702.100629.|
Near full-length genomes of 4 unclassified HIV-1 variants infecting patients enrolled in an antenatal cohort in Canada were obtained by sequencing. All 4 variants showed original recombination profiles, including A1/A2/J, A1/D, and A1/G/J/CRF11_cpx structures. Identification of these variants highlights the growing prevalence of unique recombinant forms of HIV-1 in North America.
HIV-1 displays extensive genetic diversity. Group M includes 9 subtypes and >45 circulating recombinant forms (CRFs) (1). In western and central Africa, where the highest levels of HIV-1 genetic heterogeneity are observed, most subtypes cocirculate along with CRFs and unique recombinant forms (URFs). This diversity may complicate diagnosis and treatment of HIV infection and represents a challenge for vaccine design. In North America, the HIV-1 epidemic is dominated by subtype B; non-B subtypes are infrequently reported (2,3). Nonetheless, recent studies have shown a growing prevalence of non-B variants (4,5). In 2005, Akouamba et al. reported high levels of HIV-1 genetic diversity among participants in the Centre Maternel et Infantile sur le SIDA (CMIS) antenatal cohort of Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal, Canada (6). Of these patients, 44 of 103 were infected with non-B subtypes, including 4 variants that failed to group within known subtypes in phylogenetic analyses (6). We performed near full-length genomic sequencing to characterize these 4 unassigned variants.
All 4 patients were newcomers to Canada from sub-Saharan Africa who received prenatal care at CMIS during 1999–2003 (6). Patient TV721 emigrated from the Democratic Republic of Congo, TV749 from Congo, and TV725 and TV919 from Rwanda. HIV-1 viral loads at study entry, measured by the Versant HIV-1 RNA 3.0 assay (bDNA) (Bayer, Pittsburgh, PA, USA), with a limit of detection of 50 RNA copies/mL plasma, were 164–23,369 RNA copies/mL plasma. CD4+ T cell counts ranged from198 cells/mm3 to 816 cells/mm3 (Table). Standardized clinical follow-up, including antiretroviral prophylaxis and treatment, was provided to all women and their children. This study was conducted according to the guidelines of the Ethics Review Board of CHU Sainte-Justine.
Viral RNA was extracted from serum and amplified by using custom-designed primers and the QIAGEN OneStep reverse transcription–PCR (QIAGEN, Mississauga, ON, Canada) (sequences available on request). For each isolate, 14–20 amplicons spanning the complete genome were generated and subcloned into pCR 2.1 TOPO (Invitrogen, Carlsbad, CA, USA). For each amplicon, we sequenced 3–10 independent clones (Beckman-Coulter, Palo Alto, CA, USA). Chromatograms were edited with Chromas version 1.45 (Technelysium, Southport, Queensland, Australia). Overlapping segments were aligned by using ClustalX version 1.81 (7) and assembled manually. Consensus sequences were generated by selecting the most frequent nucleotide at each position. We performed bootscan analyses according to the neighbor-joining method and Kimura 2-parameter distances using a 300-nt window and 10-nt increments (Simplot 3.5.1) (8). These parameters allow accurate localization of recombination breakpoints in HIV-1 recombinants (9). We computed phylogenetic reconstructions based on the neighbor-joining method and Kimura 2-parameter distances by using MEGA4 (10) to confirm recombinant structures. Bootstrap values >80% were considered significant.
Complete HIV-1 genomic sequences were obtained from patients TV721 (9,794 nt) and TV749 (9,791 nt). Genomic coverage of 79.3% and 91.6% was achieved for patients TV725 (7,763 nt) and TV919 (8,905 nt), respectively. On the basis of HXB2 numbering (1), missing regions were located between positions 545–1411 and between 6946–7930 for patient TV725, and between positions 7138 and 7834 for patient TV919. Screening of HIV-1 genomic sequences from patient TV721 with the HIVdb Genotypic Resistance Interpretation Algorithm (http://hivdb6.stanford.edu/asi/deployed/HIVdb.html) showed minor resistance mutations to protease inhibitors (L10I) and integrase inhibitors (I203M). Mutations associated with minor resistance to protease inhibitors (L10I) and non-nucleoside reverse transcription inhibitors (E138A) were detected in sequences from patient TV919, and a mutation conferring high-level resistance to delavirdine (P236L) was detected in patient TV725. In contrast, sequences from patient TV749 did not show mutations associated with resistance to antiretroviral agents (11). Previous subtyping, based on phylogenetic analyses of pol gene sequences, showed that sequences from patients TV721 and TV749 grouped together (100% bootstrap) but only loosely with clade J references (61% bootstrap); sequences from patients TV725 and TV919 grouped outside all major clades (6). Bootscan analysis showed complex recombinant structures for all 4 full-length or near full-length genomes (Figure). Sequences derived from patients TV721 and TV749 comprised regions from subtype J but were also similar to subtypes A1 and A2 (Figure). Examination of the homology, position, and sharing of recombination breakpoints suggests that HIV-1 isolates infecting patients TV721 and TV749 may be closely related recombinants, perhaps resulting from common-source transmission or representing a novel CRF or URF. Reciprocal bootscan analyses that included subtypes A1, A2, and J supported this assessment (data not shown). However, a review of the medical files and case histories of patients TV721 and TV749 did not confirm epidemiologic relatedness. Although multiple CRFs and URFs contain segments related to subtypes A and J, sequences from patients TV721 and TV749 are 2 of only 3 full-length HIV-1 genomes reported that exclusively comprise sequences related to subtypes A and J (12). The genomic structure of 98BW21.17 resembles that of sequences from patients TV721 and TV749 in terms of chimerism, but the location of recombination breakpoints is distinct (data not shown).
Sequences from patients TV725 and TV919 grouped outside all major clades in phylogenetic analyses of pol gene sequences (6). Bootscan analysis of the HIV-1 strain infecting patient TV725 clearly demonstrated that this variant comprised segments most closely related to subtypes A1 and D (Figure). Sequences from patient TV725 display a recombination pattern resembling that of CRF35_AD, the only other A1/D intersubtype recombinant described, which was recently identified in Kabul, Afghanistan (13). CRF35_AD and TV725 share A1 backbones, and recombination points bordering clade D segments are comparatively close (positions 2166–2444 for CRF35_AD and 2133–2360 for the isolate infecting patient TV725; positions 2901–3538 for CFR35_AD and 2897–3659 for TV725). However, they differ with respect to a clade D–related segment at positions 9044–9489 in TV725 (Figure). Finally, analysis of TV919 sequences showed complex A1/G/J mosaicism and similarities with CRF11_cpx, in terms of clade composition and localization of recombination breakpoints (14). Including the CRF11_cpx reference sequence 95CM1816 in bootscan analysis highlighted the similarities between sequences from patient TV919 and CRF11_cpx (Figure), which extends from positions 3227 to 7137 and includes segments corresponding to subtypes A1, G, and J. The most distinctive difference between the isolate infecting patient TV919 and CRF11_cpx started at position 7835; the former sequentially clustered with subtypes A1, J, and G, CRF11_cpx closely associated with subtypes J, A1, and E. Thus, the isolate infecting patient TV919 represents a novel A/G/J/CRF11_cpx recombinant. The HIV-1 isolates that infected patients TV721, TV725, TV749, and TV919 had more recombination breakpoints and unclassified regions than most CRFs and URFs, highlighting their unique recombination profiles and structural complexity.
We identified novel HIV-1 recombinants infecting pregnant women in Montreal. None of the 4 patients transmitted HIV-1 to their children. No evidence was found that these particular variants currently circulate within the Canadian population. Thus, the HIV-1 isolates infecting patients TV721, TV725, TV749, and TV919 must be construed as URFs. In North America, only 1 URF, also isolated in Montreal, was characterized by near full-length genomic sequencing (5). Given the ongoing movement of the population from areas where the disease is endemic into regions in which subtype B predominates, reports of novel HIV-1 recombinants are likely to increase and include complex mosaic genomes. Biological properties of recombinant subtypes might differ from those of other clades, particularly in terms of HIV disease progression (15) and drug resistance. In terms of public health, antenatal cohorts represent unique sentinel sites to monitor the emergence of novel HIV-1 variants, including complex mosaic recombinants, in countries where their prevalence is low.
Mr Quesnel-Vallières is pursuing a master of science degree and works in the Department of Microbiology and Immunology, Faculty of Medicine, Université de Montréal. His research interests are viral diversity in HIV infection and hepatitis C.
We thank Silvie Valois and Martine Caty for expert technical assistance.
This study was supported in part by grants from the Canadian Institutes of Health Research (HOP-75352) and from the Réseau SIDA-Maladies Infectieuses of the Fonds de la Recherche en Santé du Québec to H.S.
- Leitner T, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, In: Theoretical Biology and Biophysics Group, editors. HIV sequence compendium 2005. Los Alamos (NM): Los Alamos National Laboratory; 2005.
- Brodine SK, Mascola JR, Weiss PJ, Ito SI, Porter KR, Artenstein AW, Detection of diverse HIV-1 genetic subtypes in the USA. Lancet. 1995;346:1198–9.
- Weidle PJ, Ganea CE, Irwin KL, Pieniazed D, McGowan JP, Olivo N, Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: a sentinel site for monitoring HIV genetic diversity in the United States. J Infect Dis. 2000;181:470–5.
- Lin HH, Gaschen BK, Collie M, El-Fishaway M, Chen Z, Korber BT, Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City. J Acquir Immune Defic Syndr. 2006;41:399–404.
- Ntemgwa M, Toni TD, Brenner BG, Routy JP, Moisi D, Oliveira M, Near full-length genomic analysis of a novel subtype A1/C recombinant HIV type 1 isolate from Canada. AIDS Res Hum Retroviruses. 2008;24:655–9.
- Akouamba BS, Viel J, Charest H, Merindol N, Samson J, Lapointe N, HIV-1 genetic diversity in antenatal cohort, Canada. Emerg Infect Dis. 2005;11:1230–4.
- Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997;25:4876–82.
- Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkami SS, Novak NG, Full-length human immunodeficiency virus type 1 genomes from subtype C–infected seroconverters in India, with evidence of intersubtype recombination. J Virol. 1999;73:152–60.
- Zhang C, Ding N, Wei JF. Different sliding window sizes and inappropriate subtype references result in discordant mosaic maps and breakpoint locations of HIV-1 CRFs. Infect Genet Evol. 2008;8:693–7.
- Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:1596–9.
- Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42:1608–18.
- Novitsky VA, Gaolekwe S, McLane MF, Ndung’u TP, Foley BT, Vannberg F, HIV type 1 A/J recombinant with a pronounced pol gene mosaicism. AIDS Res Hum Retroviruses. 2000;16:1015–20.
- Saunders-Buell E, Saad MD, Abed AM, Bose M, Todd CS, Strathdee SA, A nascent HIV type 1 epidemic among injecting drug users in Kabul, Afghanistan is dominated by complex AD recombinant strain, CRF35_AD. AIDS Res Hum Retroviruses. 2007;23:834–9.
- Wilbe K, Casper C, Albert J, Leitner T. Identification of two CRF11-cpx genomes and two preliminary representatives of a new circulating recombinant form (CRF13-cpx) of HIV type 1 in Cameroon. AIDS Res Hum Retroviruses. 2002;18:849–56.
- Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis. 2008;197:707–13.
- Figure. Genetic organization and recombination breakpoints in HIV-1 genomic sequences isolated from patients TV721 (A), TV725 (B), TV749 (C), and TV919 (D). Nucleotide sequences were submitted to GenBank (accession nos. HM215249–HM215252)....
TableCite This Article
Please use the form below to submit correspondence to the authors or contact them at the following address:
Hugo Soudeyns, Unité d’Immunopathologie Virale, Centre de Recherche du CHU Sainte-Justine, 3175 Côte Sainte-Catherine, Rm 6735, Montréal, QC H3T 1C5, Canada
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: July 08, 2011
- Page last updated: July 08, 2011
- Page last reviewed: July 08, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)